In therapeutic aspect, CEACAM6, functioning as an immunosuppressive modulator, and its targeted antibody tinurilimab, have been utilized in preclinical studies for the treatment of solid tumors.[20] The high uptake and excellent tumor contrast of 89Zr‐Df‐tinurilimab indicated that tinurilimab was suitable for conjugating therapeutic nuclides in the context of radioimmunotherapy. This evidence concerns the gene CEACAM6 and neoplasm.